Tempus AI
By Tempus AI, Inc.
Tempus AI is a precision medicine company that combines clinical and molecular data, including genomic sequencing results, with machine learning to help oncologists and other clinicians choose treatments tailored to an individual patient's…
Definition
Tempus AI is a precision medicine company that combines clinical and molecular data, including genomic sequencing results, with machine learning to help oncologists and other clinicians choose treatments tailored to an individual patient's disease profile. It operates as both a diagnostics laboratory and a data and software platform used by hospitals and pharmaceutical companies. Beyond oncology, it has extended the same approach to cardiology and mental health, licensing structured real-world datasets to drug developers alongside its clinician-facing sequencing and decision-support business.
Overview
Tempus AI grew out of the observation that most clinical decisions in oncology are still made without systematic access to the molecular data that increasingly determines how a cancer will respond to a given therapy. Genomic information about a tumor's mutations is often available somewhere in a health system, but scattered across lab reports, imaging studies, and clinical notes that are not organized for quick reference at the point of care. The company built a genomic sequencing lab alongside a software platform that organizes structured clinical records, imaging, and sequencing results into a single view a clinician can use when deciding on a treatment plan. On the diagnostics side, Tempus offers next-generation sequencing panels that profile tumors for mutations relevant to targeted therapies and clinical trial eligibility. Results are returned to ordering physicians alongside decision-support content summarizing which treatments or trials might be relevant given the detected mutations, rather than as a raw sequencing report alone that a physician would need to interpret without additional context on what each mutation implies for treatment options. The machine learning component of the platform is applied both to help interpret this molecular and clinical data and to support the pharmaceutical industry side of the business, where Tempus licenses de-identified, structured real-world datasets to drug developers for trial design and biomarker discovery. This dual business model, serving clinicians directly while also monetizing data infrastructure for life sciences companies, is central to how the company positions itself against pure diagnostics labs that do not build a parallel data-licensing business alongside their lab operations. Tempus has expanded beyond oncology into areas such as cardiology and mental health, applying the same pattern of combining structured multimodal data with predictive models trained to find patterns across large patient populations. It also builds algorithms intended to flag patients who may benefit from further testing, such as models that screen echocardiogram data for signs of underlying heart conditions that might otherwise go unnoticed until later in a disease's progression. As with other companies operating at the intersection of genomics and AI, Tempus's value depends on data quality and the reliability of its models across diverse patient populations, since a model trained predominantly on one demographic group may perform less reliably on others. Its recommendations are intended to inform, not replace, a treating physician's clinical judgment, and the company's dual clinical and data-licensing business model means its incentives sit somewhat differently than a laboratory that only sells diagnostic tests. In practice, adoption of Tempus's platform tends to happen at the level of an individual oncology practice or hospital cancer program deciding to route tumor samples to its lab rather than a competing sequencing provider, a decision often influenced by turnaround time, the breadth of the mutation panel offered, and how well the resulting report integrates with the ordering physician's existing workflow. Pharmaceutical partners engage separately, licensing datasets or contracting for specific analyses tied to a drug program rather than purchasing sequencing services directly. Choosing Tempus over a narrower diagnostics-only lab typically reflects a preference for a platform that also aggregates data across a patient's full record, while a hospital with lower data-integration needs may find a simpler, single-purpose sequencing vendor sufficient for its purposes.
Key Features
- Next-generation sequencing panels for tumor genomic profiling
- Software platform unifying clinical, imaging, and molecular patient data
- Machine learning models supporting treatment and trial-matching decisions
- Real-world data licensing for pharmaceutical trial design and biomarker research
- Expansion of predictive algorithms into cardiology and mental health
- Integration with hospital and oncology practice workflows